Ultralife Corporation reported a decrease in revenue and operating income for the second quarter of 2020 compared to the same period in 2019. However, the company's adjusted earnings per share of $0.13 reflects the benefits of end-market diversity and a resilient business model despite business disruptions caused by the pandemic.
Battery and Energy Products' medical sales increased 72% year-over-year.
Government/defense sales increased 50% year-over-year.
Commercial sales increased 7.5% while government/defense sales decreased 13.7% from the 2019 period.
These orders were completed in the second quarter of 2020.
Ultralife's second quarter adjusted earnings per share of $0.13 cents reflects the benefits of our end-market diversity and resilient business model in the face of continued business disruptions caused by the pandemic.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance